NASDAQ : TARS
Tarsus Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 74.85 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.28B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.28B |
| Enterprise Value | 2.92B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 43.88M |
| Shares Outstanding | 43.88M |
| Shares Change (YoY) | +7.95% |
| Shares Change (QoQ) | +1.02% |
| Owned by Insiders (%) | 3.06% |
| Owned by Institutions (%) | 88.63% |
| Float | 32.74M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.42 |
| Forward PS | 3.97 |
| PB Ratio | 9.34 |
| P/TBV Ratio | 9.67 |
| P/FCF Ratio | 58.65 |
| P/OCF Ratio | 44.29 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 52.21 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.20 |
| Quick Ratio | 3.12 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.59 |
| Interest Coverage | -5.54 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -13.68% |
| Return on Assets (ROA) | -5.48% |
| Return on Invested Capital (ROIC) | -7.22% |
| Return on Capital Employed (ROCE) | -11.15% |
| Weighted Average Cost of Capital (WACC) | 6.73% |
| Revenue Per Employee | $1.64M |
| Profits Per Employee | -$125,611 |
| Employee Count | 370 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 25.47 |
Taxes
| Measure | Value |
|---|
| Income Tax | 7.13M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +10.86% |
| 50-Day Moving Average | 75.16 |
| 200-Day Moving Average | 67.78 |
| Relative Strength Index (RSI) | 55.11 |
| Average Volume (20 Days) | 921,113 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.73M |
| Short Previous Month | 6.07M |
| Short % of Shares Out | 13.06% |
| Short % of Float | 17.51% |
| Short Ratio (days to cover) | 6.62 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 606.33M |
| Gross Profit | 501.26M |
| Operating Income | -48.54M |
| Pretax Income | -39.35M |
| Net Income | -46.48M |
| EBITDA | -46.20M |
| EBIT | -48.54M |
| Loss Per Share | -$1.08 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 449.69M |
| Total Debt | 88.81M |
| Net Cash | 360.88M |
| Net Cash Per Share | $8.22 |
| Equity (Book Value) | 346.73M |
| Book Value Per Share | 8.01 |
| Working Capital | 386.24M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 74.16M |
| Capital Expenditures | -18.16M |
| Depreciation & Amortization | 2.34M |
| Net Borrowing | n/a |
| Free Cash Flow | 56.00M |
| FCF Per Share | $1.28 |
Margins
| Measure | Value |
|---|
| Gross Margin | 82.67% |
| Operating Margin | -8.00% |
| Pretax Margin | -6.49% |
| Profit Margin | -7.67% |
| EBITDA Margin | -7.62% |
| EBIT Margin | -8.00% |
| FCF Margin | 9.24% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.95% |
| Shareholder Yield | -7.95% |
| Earnings Yield | -1.45% |
| FCF Yield | 1.71% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $98.89 |
| Price Target Difference | 32.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 36.24% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 6.66 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |